The Joint Corp. (JYNT) P/E Ratio History
Deep ValueTrading at 43.8x · 10th percentile of 5-year range · Significant discount to historical valuation · Data 2018–2026
Loading P/E history...
P/E Ratio Analysis
As of June 30, 2026, The Joint Corp. (JYNT) trades at a price-to-earnings ratio of 43.8x, with a stock price of $8.33 and trailing twelve-month earnings per share of $0.23.
The current P/E is 49% below its 5-year average of 85.5x. Over the past five years, JYNT's P/E has ranged from a low of 29.2x to a high of 228.0x, placing the current valuation at the 10th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.9x, JYNT trades at a 91% premium to its sector peers. The sector includes 231 companies with P/E ratios ranging from 0.0x to 191.6x.
Relative to the broader market, JYNT commands a significant premium over the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our JYNT DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
JYNT Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
JYNT P/E vs Peers
Outpatient clinics and surgery centers peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $272M | 15.3 | 10.26 | +96%Best | |
| $1B | 48.5 | - | -23% | |
| $9B | 27.1 | 1.96 | +14% | |
| $2B | 18.8 | 0.93Best | +23% | |
| $381B | 31.7 | - | -15% | |
| $132B | 74.5 | - | -62% | |
| $73B | 12.6Lowest | - | +83% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
JYNT Historical P/E Data (2018–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | - | $8.85 | $0.22 | 40.0x | -62% |
| FY2025 Q4 | Dec 31 2025 | $8.72 | $0.18 | 47.9x | -55% |
| FY2023 Q3 | Sep 30 2023 | $8.99 | $0.14 | 66.3x | -37% |
| FY2023 Q2 | Jun 30 2023 | $13.50 | $0.23 | 57.7x | -45% |
| FY2023 Q1 | Mar 31 2023 | $16.83 | $0.27 | 62.3x | -41% |
| FY2022 Q4 | Dec 31 2022 | $13.98 | $0.10 | 145.9x | +38% |
| FY2022 Q3 | Sep 30 2022 | $15.71 | $0.07 | 228.0x | +115% |
| FY2022 Q2 | - | $15.31 | $0.15 | 102.8x | -3% |
| FY2022 Q1 | - | $35.39 | $0.31 | 115.8x | +9% |
| FY2021 Q4 | Dec 31 2021 | $65.69 | $0.48 | 136.9x | +29% |
| FY2021 Q3 | - | $98.02 | $1.19 | 82.4x | -22% |
| FY2021 Q2 | Jun 30 2021 | $83.92 | $1.17 | 71.7x | -32% |
| FY2021 Q1 | Mar 31 2021 | $48.37 | $1.00 | 48.4x | -54% |
| FY2020 Q4 | - | $26.26 | $0.90 | 29.2x | -72% |
| FY2020 Q3 | Sep 30 2020 | $17.39 | $0.27 | 64.4x | -39% |
| FY2020 Q2 | - | $15.27 | $0.20 | 76.3x | -28% |
| FY2020 Q1 | - | $10.85 | $0.22 | 49.3x | -53% |
| FY2019 Q4 | - | $16.14 | $0.23 | 70.2x | -34% |
| FY2019 Q3 | Sep 30 2019 | $18.61 | $0.20 | 93.0x | -12% |
| FY2019 Q2 | Jun 30 2019 | $18.20 | $0.15 | 122.2x | +16% |
| FY2019 Q1 | Mar 31 2019 | $15.75 | $0.12 | 136.0x | +29% |
| FY2018 Q4 | Dec 31 2018 | $8.32 | $0.02 | 480.9x | +355% |
Average P/E for displayed period: 105.8x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
8+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
JYNT — Frequently Asked Questions
Quick answers to the most common questions about buying JYNT stock.
What is JYNT's P/E ratio?
The Joint Corp. (JYNT) trailing twelve-month P/E ratio is 43.8x, based on TTM diluted EPS of $0.23. The 5-year average P/E is 85.5x and the historical range spans 29.2x to 228.0x.
Is JYNT stock overvalued or undervalued?
JYNT trades at 43.8x P/E, below its 5-year average of 85.5x. At the 10th percentile of its historical range (29.2x–228.0x), the stock is priced at a discount to its own history.
Is JYNT stock expensive?
No, JYNT is not expensive on a historical basis. The current P/E of 43.8x is below the 5-year average of 85.5x and sits at the 10th percentile of its valuation range.
What is JYNT's historical P/E range?
Over the past 5 years, JYNT's P/E ratio has ranged from 29.2x to 228.0x, with a median of 71.7x and an average of 85.5x. The current P/E of 43.8x places the stock at the 10th percentile of this range. Full historical data spans 2018–2026.
How does JYNT's P/E compare to the S&P 500?
JYNT trades at 43.8x P/E versus the S&P 500 median of 25.1x. The 75% premium to the market typically reflects higher expected earnings growth or quality.
How does JYNT's valuation compare to Healthcare peers?
The Joint Corp. P/E of 43.8x compares to the Healthcare sector median of 22.9x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is JYNT's PEG ratio?
JYNT PEG ratio is N/A, based on a P/E of 43.8x and EPS growth of 148.7%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is JYNT's earnings yield?
JYNT earnings yield is 2.28%, the inverse of its 43.8x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.